Despite robust in vitro cytotoxicity against tumour targets such as melanoma, adoptive NK cell transfer has yielded limited clinical efficacy, often due to suppressive factors within the TME, including downregulation of activating receptors such as NKG2D (78). The gene discussed is KLRK1; the disease is neoplasm.